What biomarker testing is recommended for early stage Lung Cancer

Lung CancerMay 15, 2026Navis AI

Ask Navis about your situation

This answer is general. Get one about your specific case — no signup, answered right here.

or Upload your records for answers about your actual case

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Biomarker Testing for Early-Stage Lung Cancer

Great question—biomarker testing is an important part of understanding your lung cancer and determining the best treatment options. Let me explain what's recommended and why.

What Biomarkers Are

Biomarkers are biological clues or markers in your cancer cells that differ from person to person. According to the NCCN Guidelines for Early and Locally Advanced Non-Small Cell Lung Cancer, biomarker testing helps your doctors understand your specific cancer and choose treatments that are most likely to work for you.

When Biomarker Testing Is Recommended

Important distinction: Biomarker testing isn't needed for very small lung tumors because surgery alone typically has excellent results. However, for most people with early-stage NSCLC who will receive treatment beyond surgery, biomarker testing is recommended.

Your care team will use biomarker testing to decide which systemic therapies (whole-body drug treatments) might be options before and after surgery.

Key Biomarkers to Test For

According to NCCN Guidelines, biomarker testing for early-stage lung cancer typically includes:

PD-L1 Expression

PD-L1 is a protein on the surface of cancer cells that helps them hide from your immune system
Testing shows how much PD-L1 your cancer cells have
This helps determine if immunotherapy (drugs that boost your immune system) might work well for you

EGFR Mutations

EGFR is a receptor on cancer cell surfaces that receives growth signals
Some mutations make this receptor overactive, causing cancer cells to grow quickly
If you have an EGFR mutation, targeted therapy drugs can specifically block this overactive signal
Common EGFR mutations include exon 19 deletions and exon 21 (L858R) mutations

Other Driver Mutations

According to the NCCN Guidelines, testing should also assess for:

ALK rearrangements (gene fusions)
ROS1 rearrangements
BRAF mutations (particularly the V600E mutation)
MET exon 14 skipping mutations
NTRK fusions
RET rearrangements
KRAS mutations (a prognostic marker indicating tumor behavior)
HER2 (ERBB2) mutations

How Testing Is Done

NCCN Guidelines recommend:

Tissue-based testing from your biopsy or surgery is preferred
Broad molecular profiling (testing multiple genes at once) is strongly advised
Next-generation sequencing (NGS) is commonly used—it can test many genes simultaneously
Testing can take up to 3 weeks for results
If there isn't enough tissue, a blood sample (plasma) may be tested for biomarkers

Important Points to Remember

✓ Tissue is preferred over blood testing for diagnosis and initial biomarker assessment

✓ Multiple biomarkers matter—your cancer might have one driver mutation, but testing for several helps ensure you don't miss treatment options

✓ Results guide treatment decisions—finding a specific mutation like EGFR or ALK can open up targeted therapy options that may work better than chemotherapy alone

✓ Ask for your pathology report—Request a copy of your pathology report from your care team and ask them to review the biomarker results with you

Questions to Ask Your Healthcare Team

What biomarkers were tested on my tumor, and what were the results?
If not all biomarkers were tested, why not, and should additional testing be done?
Based on my biomarker results, what treatment options are available to me?
If my tumor doesn't have a known biomarker, what does that mean for my treatment?
Will my biomarkers be retested if my cancer progresses or doesn't respond to treatment?

Why This Matters for Your Care

According to NCCN Guidelines, biomarker testing is essential because:

Patients with specific driver mutations often benefit from targeted therapies, which can be more effective and have different side effects than chemotherapy
The results help your oncology team personalize your treatment plan
It ensures you're not missing potentially better treatment options

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Ask Navis about your case

That answer is general. Ask about your specific situation — no signup, answered right here.

or Upload your records for answers about your actual case

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →